BOSTON and DAEJEON, South Korea, Jan. 4, 2026 — Orum Therapeutics, a biotechnology company pioneering degrader-antibody conjugates (DACs), announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). The leadership move strengthens Orum’s scientific foundation as it advances its Dual-Precision Targeted Protein Degradation (TPD²®) platform and prepares multiple oncology programs for key preclinical and clinical milestones.
Science Significance
The appointment underscores Orum’s commitment to next-generation therapeutic science, particularly in the rapidly evolving field of targeted protein degradation. DACs combine the cell-selective targeting power of antibodies with intracellular protein degradation payloads, offering a new approach to address previously undruggable cancer targets. Dr. May’s deep experience in antibody-drug conjugates (ADCs), T-cell engagers, and structure-guided platform design directly supports Orum’s ambition to engineer first-in-class, precision degraders. Under his leadership, Orum aims to accelerate translation from discovery into robust, biologically validated clinical candidates.
Regulatory Significance
From a cGxP and regulatory affairs perspective, strengthening scientific leadership at this stage is critical as Orum’s programs move toward IND-enabling studies and early clinical development. DACs represent a complex modality, requiring rigorous control over conjugation chemistry, payload consistency, target specificity, and preclinical safety assessment. Dr. May’s track record advancing programs through IND preparation and clinical entry supports regulatory readiness under GLP and GCP frameworks. His oversight is expected to reinforce data integrity, translational rigor, and regulatory-aligned development strategies as Orum engages with global health authorities.
Business Significance
Advertisement
Strategically, the CSO appointment signals Orum’s evolution from a platform-focused innovator to a pipeline-driven oncology company. Experienced scientific leadership is a key value driver for biopharma partnerships, investor confidence, and long-term portfolio growth. Dr. May’s background includes leadership roles across biotech and large pharmaceutical organizations, where he advanced multiple programs into the clinic and supported build-to-buy and acquisition-driven growth models. For Orum, this enhances its positioning as a credible partner in the competitive oncology innovation landscape, particularly as interest grows in degrader-based therapeutics.
Patients’ Significance
Although still in development, Orum’s DAC programs are ultimately designed to benefit patients with hard-to-treat cancers that have limited therapeutic options. By enabling cell-specific degradation of disease-driving proteins, DACs may offer greater efficacy with reduced off-target toxicity compared to conventional therapies. Strong scientific leadership increases the likelihood that programs advance efficiently and safely, supporting the long-term goal of delivering more precise, durable cancer treatments to patients with high unmet medical need.
Policy Significance
At a broader policy level, Orum’s focus on DACs reflects growing momentum around innovative therapeutic modalities that challenge existing regulatory paradigms. Health authorities and policymakers are increasingly tasked with adapting guidance to accommodate novel biologic-small molecule hybrids, such as DACs and other targeted degraders. Leadership with experience navigating emerging modality regulation helps ensure that innovation progresses in parallel with patient safety, quality standards, and transparent governance. Orum’s advancement contributes to shaping future regulatory frameworks for protein degradation-based medicines.
The appointment of Chad May as Chief Scientific Officer marks a strategic inflection point for Orum Therapeutics as it scales its degrader-antibody conjugate platform toward clinical impact. By aligning deep scientific expertise with disciplined, cGxP-ready development, Orum strengthens its ability to translate cutting-edge protein degradation science into meaningful oncology therapies. As the DAC field matures, leadership decisions such as this will play a defining role in determining which innovators successfully move from concept to clinic.
Source: Orum Therapeutics press release
